BioCanRx
Box 611, 501 Smyth Road K1H 8L6 Ottawa, ON, Canada

Mark your calendars! BioCanRx and Stem Cell Network - Réseau de cellules souches are co-hosting a virtual session focused on mental health in academia. The webinar will include an expert panel discussion as well as helpful resources and strategies. Register here: https://us02web.zoom.us//register/WN_WeqlHvgxQ_mDQY3FT-FtIw

Health Canada Approves KEYTRUDA (pembrolizumab) as First-line Treatment for Adults with Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer. Learn more: https://bit.ly/3bwxKky

The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta) for patients with follicular lymphoma that has returned or worsened despite earlier treatment: https://bit.ly/30lQmxr

On International Women's Day, President & CEO Stéphanie Michaud speaks to the importance of equity & inclusion. In support of this, BioCanRx has joined Canadian Innovation's 50-30 challenge to help forge an inclusive world!

Great to be working with The Cell Therapy Lab at CancerCare Manitoba News, and partners in Toronto, Victoria and Ottawa, on this important point of care manufacturing network!

Big news! BioCanRx is thrilled to announce Dr. Carl June of Perelman School of Medicine at the University of Pennsylvania and the Parker Institute for Cancer Immunotherapy as keynote speaker for the 2021 Summit for Cancer Immunotherapy! Stay tuned to www.cancersummit.ca for more details.

The Ottawa Hospital - L'Hôpital d'Ottawa Biotherapeutics Manufacturing Centre, a BioCanRx-supported facility, is hosting a groundbreaking new program that offers students hands-on GMP biomanufacturing training. BioCanRx's Dr. Jennifer Quizi discusses this initiative in the Ottawa Citizen: https://ottawacitizen.com/news/local-news/the-right-stuff

This coming Monday: the first session in our free virtual Summit Speaker Series with BioCanRx network investigators! The featured topic is Canada's CAR T-cell capacity. Register here: https://bit.ly/2Huhjcv

In case you missed Monday's Summit4CI Speaker Series session on CAR T-cell Therapy in Canada, the webinar recording is now posted: https://bit.ly/3lNbpSA Thanks again to all the participants!

Just one week until we begin our free virtual Summit Speaker Series with BioCanRx network investigators! The first session is all about building Canada's CAR T capacity. Registration and full details: https://bit.ly/2Huhjcv

FYI: The Canadian Cancer Research Alliance is seeking researcher and patient/family advisor feedback in a survey regarding priorities for cancer-related health services and policy research. The deadline is Nov. 20 - participate here: https://bit.ly/2IbIVmW

"Usually you would think that for two types of cancers that generally respond well to immunotherapy, there would be similar principles in terms of characteristics of patients who benefit, but that's not the case in this instance." New study out of UCLA Jonsson Comprehensive Cancer Center identifies patients with lung cancer most likely to respond to immunotherapy: https://medicalxpress.com//2020-11-patients-lung-cancer-im

Supporting Canada’s biomanufacturing ecosystem: BioCanRx's Jen Quizi and Megan Mahoney share their thoughts on 'CanPRIME - A novel & necessary model for integrated training' in a CSPC (Canadian Science Policy Centre) 2020 conference editorial. Read it here: https://bit.ly/3poUgAJ

A new clinical trial is taking place at Seattle Children's Hospital - for the first time, a patient is being treated with CAR T therapy for a deadly childhood brain cancer called called diffuse intrinsic pontine glioma (DIPG): https://www.forbes.com//first-patient-treated-with-experi/